<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111579</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP123</org_study_id>
    <nct_id>NCT00111579</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)</brief_title>
  <official_title>A Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With Trivalent Inactivated Vaccine (TIV) in Children 6 to &lt;36 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and&#xD;
      TIV against homotypic and heterotypic influenza virus strains.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The following immunogenicity endpoints: The strain-specific HAI seroconversion rates (≥ 4-fold increase) among baseline seronegative participants (HAI titer ≤ 1:4), by dose number</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of participants achieving ≥ 4-fold increase in strain-specific HAI titer from baseline in all participants regardless of baseline serostatus, by dose number</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints include: AEs SAEs and significant new medical conditions for all participants</measure>
    <time_frame>Day 28 post vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>52</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAIV-T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TIV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAIV-T</intervention_name>
    <description>A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TIV</intervention_name>
    <description>A total vol. of 0.25 will be administered intramuscularly for each of two doeses.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Ages 6 to but less than 36 months (reached their 6th month but have not yet reached&#xD;
             their 3rd birthday) at the time of randomization&#xD;
&#xD;
          -  Written informed consent and Health Insurance Portability and Accountability Act&#xD;
             (HIPAA) authorization (if applicable) obtained from the participant's parent/legal&#xD;
             representative&#xD;
&#xD;
          -  Ability of the parent/legal representative to understand and comply with the&#xD;
             requirements of the study&#xD;
&#xD;
          -  Parent/legal representative available by telephone&#xD;
&#xD;
          -  Ability to complete follow-up period of 180 days after final study vaccination, as&#xD;
             required by the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to any component of CAIV-T or TIV, including egg or egg&#xD;
             products, monosodium glutamate, porcine gelatin or thimerosal&#xD;
&#xD;
          -  History of hypersensitivity to gentamicin&#xD;
&#xD;
          -  Any known immunosuppressive condition or immune deficiency disease (including HIV&#xD;
             infection), or ongoing receipt of any immunosuppressive therapy&#xD;
&#xD;
          -  Household contact who is immunocompromised (participants should also avoid close&#xD;
             contact with immunocompromised individuals for at least 21 days after each study&#xD;
             vaccination)&#xD;
&#xD;
          -  History of Guillain-Barre syndrome&#xD;
&#xD;
          -  Medically diagnosed wheezing, bronchodilator use, or steroid use (systemic or&#xD;
             inhaled), by parent/legal representative report or chart review, within the 42 days&#xD;
             prior to randomization (i.e., children with recent persistent asthma are excluded); or&#xD;
             history of severe persistent asthma, according to the criteria described in the&#xD;
             National Asthma Education and Prevention Program (NAEPP) Expert Panel Report:&#xD;
             Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002&#xD;
&#xD;
          -  Acute febrile (not greater than 100.0 degrees F oral or equivalent) and/or clinically&#xD;
             significant respiratory illness (e.g., cough or sore throat) within 72 hours prior to&#xD;
             either study vaccination&#xD;
&#xD;
          -  Use of aspirin or aspirin-containing products within 30 days prior to randomization,&#xD;
             or expected use through 180 days after final study vaccination&#xD;
&#xD;
          -  Receipt of any prior influenza vaccine&#xD;
&#xD;
          -  Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and&#xD;
             zanamivir) within 14 days prior to randomization, or expected use through 180 days&#xD;
             after final study vaccination&#xD;
&#xD;
          -  Administration of any live virus vaccine within 30 days prior to randomization, or&#xD;
             expected receipt through 30 days after final study vaccination&#xD;
&#xD;
          -  Administration of any inactivated (i.e., non-live) vaccine within 14 days prior to&#xD;
             randomization, or expected receipt within 14 days before, or 14 days after, either&#xD;
             study vaccination&#xD;
&#xD;
          -  Receipt of any investigational agent within 30 days prior to randomization, or&#xD;
             expected receipt through 180 days after final study vaccination (use of licensed&#xD;
             agents for indications not listed in the package insert is permitted)&#xD;
&#xD;
          -  Receipt of any blood product within 90 days prior to randomization, or expected&#xD;
             receipt through 180 days after final study vaccination&#xD;
&#xD;
          -  Family member or household contact who is an employee of the research center or&#xD;
             otherwise involved with the conduct of the study&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of the vaccine or interpretation of the study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wee Care Pediatrics</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bear Care Pediatrics</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Pediatrics</name>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <zip>84062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Pediatrics</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Families First Pediatrics</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>May 23, 2005</study_first_submitted>
  <study_first_submitted_qc>May 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2005</study_first_posted>
  <last_update_submitted>July 22, 2008</last_update_submitted>
  <last_update_submitted_qc>July 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Chris Ambrose, Dir. Medical Affairs</name_title>
    <organization>MedImmune LLC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

